Next, we optimised the assay's sensitivity by introducing a dual-antigen immunomagnetic tumour cell enrichment procedure before marker gene quantitation and by refining the panel of marker genes as follows: cytokeratin 19 (CK19), human secretory protein p1.B (p1B), human epithelial glycoprotein (EpCAM; here: EGP) and mammaglobin (MmGl) (Molloy et al, 2008). This evidence concerns the gene KRT19 and neoplasm.